PAG
CRSP icon

Private Advisor Group’s CRISPR Therapeutics CRSP Stock Holding History

Private Advisor Group’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-300
Closed -$1.88K – 2650
2025
Q3 		$1.88K Buy
+300
New +$17.2K ﹤0.01% 2534

Other funds holding CRSP

EWA
EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
SC
Slow Capital Greenbrae, California $857M AUM 38.3% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $43.3B AUM 29.3% 1-Year Est. Return
CIC
Canal Insurance Company Greenville, South Carolina $456M AUM 40.11% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
WETS
Wealth Enhancement Trust Services Sioux Falls, South Dakota $900M AUM

Private Advisor Group's CRSP Position: Q2 2026 in Review

Private Advisor Group increased its CRISPR Therapeutics (CRSP) stake by 4.2% in Q2 2026, buying an estimated $235K and bringing the position to 111,129 shares worth $6.06M. The position accounts for 0.03% of the portfolio, ranked #546.

Private Advisor Group first reported a position in CRSP in Q2 2018 and has held it in 29 quarters since. The position peaked at $7.65M in Q3 2025. 150 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Private Advisor Group held 111,129 shares of CRISPR Therapeutics worth $6.06M as of Q2 2026.
  • Private Advisor Group bought 4,467 CRISPR Therapeutics shares in Q2 2026, an estimated $235K.
  • CRISPR Therapeutics made up 0.03% of Private Advisor Group's portfolio in Q2 2026, its #546 holding.
  • Private Advisor Group first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • Private Advisor Group's CRISPR Therapeutics position peaked at $7.65M in Q3 2025.
  • 150 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Private Advisor Group's 13F filing for Q2 2026, filed 27 Jul 2026.